We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $27.71, moving -4.38% from the previous trading session. This change lagged the S&P 500's 1.62% loss on the day. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.
The company's stock has climbed by 15.78% in the past month, exceeding the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.02, marking a 111.76% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $689.29 million, indicating a 26.52% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.26 per share and revenue of $2.91 billion. These totals would mark changes of -149.06% and +23.78%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 92.39% lower within the past month. Currently, Hims & Hers Health, Inc. is carrying a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 724.5. This expresses a premium compared to the average Forward P/E of 25.06 of its industry.
We can additionally observe that HIMS currently boasts a PEG ratio of 54.37. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.6 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $27.71, moving -4.38% from the previous trading session. This change lagged the S&P 500's 1.62% loss on the day. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.
The company's stock has climbed by 15.78% in the past month, exceeding the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.02, marking a 111.76% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $689.29 million, indicating a 26.52% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.26 per share and revenue of $2.91 billion. These totals would mark changes of -149.06% and +23.78%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 92.39% lower within the past month. Currently, Hims & Hers Health, Inc. is carrying a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 724.5. This expresses a premium compared to the average Forward P/E of 25.06 of its industry.
We can additionally observe that HIMS currently boasts a PEG ratio of 54.37. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.6 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.